Alexandra Pender

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Journal: Blood advances

Published: July 26, 2023

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: April 02, 2023

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.

Journal: BMC cancer

Published: November 24, 2022

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Journal: Current oncology (Toronto, Ont.)

Published: October 26, 2022

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.

Journal: Immunotherapy advances

Published: August 17, 2022

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.

Journal: Blood

Published: December 08, 2021

Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.

Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.

Journal: Cancer medicine

Published: August 09, 2021

The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.

The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.

Journal: The Journal of molecular diagnostics : JMD

Published: July 23, 2021

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.

Journal: Translational lung cancer research

Published: September 21, 2020

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 27, 2020

Canadian Lung Cancer Conference 2019.

Canadian Lung Cancer Conference 2019.

Journal: Current oncology (Toronto, Ont.)

Published: September 25, 2019

Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.

Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.

Journal: Histopathology

Published: April 11, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026